Delving into the Latest Updates on ABP1011T with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

ABP1011T

Target

RTKs

Action

inhibitors

Mechanism

RTK inhibitors(Receptor protein-tyrosine kinase inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersRespiratory Diseases+ [3]

Active Indication

Bladder CancerEsophageal CarcinomaKidney Neoplasms+ [4]

Inactive Indication-

Originator Organization

Ab Pharma Ltd.

Active Organization

Shanghai Aibo Pharmaceutical Technology Co Ltd

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

主要目的 1) 评估ABP1011T片在局部晚期不可切除或转移性骨肉瘤患者中的有效性。次要目的 1) 评估ABP1011T片在局部晚期不可切除或转移性骨肉瘤患者中的安全性。探索性目的 1) 评估ABP1011T片在局部晚期不可切除或转移性骨肉瘤患者中的药代动力学特征。 2) 探索性研究局部晚期不可切除或转移性骨肉瘤患者生物标志物与疗效的关系。

[Translation]

Primary Objectives 1) To evaluate the efficacy of ABP1011T tablets in patients with locally advanced, unresectable, or metastatic osteosarcoma. Secondary Objectives 1) To evaluate the safety of ABP1011T tablets in patients with locally advanced, unresectable, or metastatic osteosarcoma. Exploratory Objectives 1) To evaluate the pharmacokinetic profile of ABP1011T tablets in patients with locally advanced, unresectable, or metastatic osteosarcoma. 2) To exploratoryally investigate the relationship between biomarkers and efficacy in patients with locally advanced, unresectable, or metastatic osteosarcoma.

Start Date03 Nov 2025

Sponsor / Collaborator

Shanghai Aibo Pharmaceutical Technology Co Ltd

ChiCTR2500111060

/ RecruitingPhase 2IIT

A Single-Arm, Open-Label Phase IIb Clinical Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients with Locally Advanced Unresectable or Metastatic Osteosarcoma

Start Date28 Oct 2025

Sponsor / Collaborator

Peking University People's Hospital

[+1]

100 Clinical Results associated with ABP1011T

Login to view more data

100 Translational Medicine associated with ABP1011T

Login to view more data

100 Patents (Medical) associated with ABP1011T

Login to view more data

100 Deals associated with ABP1011T

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bladder Cancer	Phase 2	China	Shanghai Aibo Pharmaceutical Technology Co Ltd	10 Nov 2025
Esophageal Carcinoma	Phase 2	China	Shanghai Aibo Pharmaceutical Technology Co Ltd	10 Nov 2025
Kidney Neoplasms	Phase 2	China	Shanghai Aibo Pharmaceutical Technology Co Ltd	10 Nov 2025
Small Cell Lung Cancer	Phase 2	China	Shanghai Aibo Pharmaceutical Technology Co Ltd	10 Nov 2025
Uterine Cervical Cancer	Phase 2	China	Shanghai Aibo Pharmaceutical Technology Co Ltd	10 Nov 2025
Advanced Malignant Solid Neoplasm	Phase 2	China	Shanghai Aibo Pharmaceutical Technology Co Ltd	03 Nov 2025
Osteosarcoma	Phase 2	China	Shanghai Aibo Pharmaceutical Technology Co Ltd	03 Nov 2025